secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001411690-25-000036
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano Genomics Q4 revenue down 24% YoY to $8.2M; full-year revenue $30.8M, down 15%
--------------------------------------------------------------------------------

- Q4 2024 revenue $8.2M vs $10.8M in Q4 2023, decline driven by discontinued clinical services; core product revenue 1% higher for full year.
- GAAP gross margin improved to 42% from 23% YoY; GAAP operating expense cut to $15.4M from $27.4M.
- Full-year product revenue $27.0M (+1% YoY) with consumables +14% and software +11%; instruments down ~$2M.
- Installed OGM systems 371 (+14% YoY); flowcell sales 30,307 (+15% YoY); 336 OGM publications in 2024.
- Cash & securities $20.9M at year-end (incl. $11.4M restricted); raised $10M in Jan 2025 offering; modified debentures to reduce payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000141169025000036/0001411690-25-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000141169025000036/bngo-20250331.htm
  HTML page:      https://secwatch.observer/filing/0001411690-25-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer